Vaccine Production Core

疫苗生产核心

• 批准号: 8294671
• 负责人: Thomas Denny
• 金额: $ 73.16万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8294671
• 关键词: AIDS/HIV problem; Administrator; Clinical Trials; Clinical trial protocol document; Collaborations; Contracts; Cyclic GMP; Development; Dolin; HIV Vaccine Trials Network; Immune response; Immunologic Monitoring; Immunology; Medical; Quality Control; Technology; Testing; TimeLine; United States National Institutes of Health; Vaccine Production; Vaccines; Work; experience; immunogenicity; pre-clinical; preclinical study; product development; programs; quality assurance; success; vaccine development; vector

Critical to the ultimate success of the CHAVI is the development of its capacity to rapidly move new discoveries and acquired technologies to testing in preclinical / clinical trials through collaboration with existing networks such as the HVTN, VRC, CAVD/Enterprise, and the NIH. In Year 3, CHAVI will ask critical questions with the current best vectors and inserts regarding insert immunogenicity and quality of the mucosal and systemic immune responses. The CHAVI Vaccine Production Core will coordinate and manage timelines required for preclinical studies in year 3.

CHAVI 最终成功的关键是发展其快速推动新事物的能力 通过与现有的合作，在临床前/临床试验中进行测试的发现和获得的技术 网络，例如 HVTN、VRC、CAVD/Enterprise 和 NIH。在第 3 年，CHAVI 将提出关键问题 与当前最好的载体和插入片段有关的插入免疫原性和粘膜和质量 全身免疫反应。 CHAVI 疫苗生产核心将协调和管理时间表 第三年临床前研究所需。